Blockchain Registration Transaction Record

Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder

Alzamend Neuro, Inc. (NASDAQ:ALZN) partners with MGH for Phase II trial of next-generation lithium therapeutic drug candidate for bipolar disorder and Alzheimer's disease, potentially revolutionizing mental health treatment.

Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder

This news matters because it highlights the potential breakthrough in next-generation treatments for mental health disorders, impacting millions of people worldwide. The partnership with MGH for clinical trials could lead to improved treatment options for bipolar disorder and Alzheimer's disease, offering hope to millions of patients and their families.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x9318ae22df243a26eec2d768a2004843a5c2a27b6594b0a563166db3ba663e52
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintmarkJU29-45c9f521d02a8673b5eb10a77be30952